Clinical Trial Update: Effect of Astragalus-based Formula: Qingshu-Yiqi-Tang on Modulating Immune Alterations in Lung Cancer Patients [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update on a Phase 2/Phase 3 study evaluating Qingshu-Yiqi-Tang, an astragalus-based formula, for modulating immune alterations in non-small cell …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Qingshu-Yiqi-Tang

Snippet

Sponsor: Chang Gung Memorial Hospital | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2, Phase 3 | Status: UNKNOWN